Melinda Daumont
About Melinda Daumont
Melinda Daumont is the WWHEOR Lead in Oncology at Bristol-Myers Squibb, based in Paris, Île-de-France, France. She has extensive experience in epidemiology and health economics, having held senior roles at Bayer, Merck, and University Medical Center Groningen.
Current Role at Bristol-Myers Squibb
Melinda Daumont has been leading the Worldwide Health Economics and Outcomes Research (WWHEOR) team in oncology at Bristol-Myers Squibb since December 2015. Based in Paris, Île-de-France, France, she focuses on health economics and outcomes research in the oncology field. Her role involves leading a team dedicated to developing and implementing strategies to assess the economic impact and health outcomes of oncology products.
Previous Roles at Bristol-Myers Squibb
Before her current role, Melinda Daumont worked at Bristol-Myers Squibb as the WWHEOR Lead at the Centre for Observational Research and Data Sciences Research from 2013 to 2015. In this role, she focused on observational research methodologies to gather and analyze data that informed the company's healthcare strategies.
Experience at Bayer and Merck
Melinda Daumont has a robust background in epidemiology, having served as a Senior Epidemiologist at Bayer from 2011 to 2012 in Berlin, Germany, and at Merck from 2009 to 2011 in Oss, North Brabant, Netherlands. Her roles included conducting epidemiological studies and providing safety advisories based on detailed safety data analyses.
Scientific Research at University Medical Center Groningen
From 2008 to 2009, Melinda Daumont worked at the University Medical Center Groningen as a Statistical Analyst and Scientific Researcher. During this period, she contributed to statistical analyses and scientific research, supporting various clinical and epidemiological studies.
Academic Background
Melinda Daumont holds a Doctor of Philosophy (PhD) from Yale University, where she studied from 2004 to 2009. Prior to that, she earned a Master of Arts (MA) from Santa Clara University, where she was enrolled from 2001 to 2004. Her academic training provided a strong foundation in research methodologies, health economics, and epidemiology.